BD Reports FY2026 Revenue Growth of 4.9% and Adjusted EPS of $12.70
BD reported fiscal 2026 revenue of $19.5B, up 4.9% YoY, and adjusted EPS of $12.70. Q4 revenue rose 5.4% to $5.3B, with adjusted EPS up 27.3% to $4.15. The company guided fiscal 2027 revenue growth to be in the low-single digits and adjusted EPS between $13.10 and $13.30. BD completed a spin-off and announced a $19B U.S. investment partnership.
How this was made
The 30-second read
Why it matters
The guidance may trigger a near‑term price dip, but long‑term catalysts such as the $19 B government partnership and new product rollouts could support upside.
Market read
Primary earnings disclosure for a large‑cap healthcare company with fresh guidance, offering actionable insight for short‑term traders.
What to watch
The $19 B government partnership and new product launches could offset short‑term guidance concerns.
Background
Becton Dickinson (BD) released its FY2026 earnings, showing modest revenue growth and issuing FY2027 guidance that signals low‑single‑digit expansion.
Ticker impact
BD reported FY2026 revenue up 4.9% and raised FY2027 adjusted EPS guidance to $13.10‑$13.30, a fresh earnings disclosure.
likely pressure as the market prices in slower revenue growth
Guidance below prior expectations for a large‑cap medical device maker typically triggers a sell‑off in the near term.
Market effects
May prompt a reassessment of growth expectations for the broader medical‑device sector.
Limited to U.S. equities; no immediate regional ripple.
Minimal global impact beyond investors tracking large‑cap healthcare stocks.
Counterpoint
If the $19 B revenue base is seen as a platform for future innovation, the stock could be undervalued despite modest guidance.
Key entities
- companyBecton Dickinson & Co.
Medical‑device manufacturer reporting FY2026 results.
